← 治験一覧に戻る
アトピー性皮膚炎患者を対象としたデュピルマブの非盲検試験
基本情報
- NCT ID
- NCT01949311
- ステータス
- 完了
- 試験のフェーズ
- 第3相
- 試験タイプ
- 介入
- 目標被験者数
- 2,733
- 治験依頼者名
- Regeneron Pharmaceuticals
概要
The primary objective is to assess the long-term safety of dupilumab administered in adult participants with atopic dermatitis (AD). The secondary objective of the study is to assess the immunogenicity of dupilumab in adult participants with AD, in the context of re-treatment, and to monitor efficacy parameters associated with long-term treatment. Optional Sub-Study: The primary objective of the sub-study is to assess the safety of the new dupilumab drug product in adult patients with AD after switching from the current dupilumab drug product. The secondary objectives of the sub-study are to evaluate systemic exposure and immunogenicity of the new dupilumab drug product in adult patients with AD.
対象疾患
Atopic Dermatitis
介入
Dupilumab(DRUG)